CN117551171A - 豌豆肽、修饰豌豆肽的制备方法及改善胃肠道功能的用途 - Google Patents
豌豆肽、修饰豌豆肽的制备方法及改善胃肠道功能的用途 Download PDFInfo
- Publication number
- CN117551171A CN117551171A CN202311359008.2A CN202311359008A CN117551171A CN 117551171 A CN117551171 A CN 117551171A CN 202311359008 A CN202311359008 A CN 202311359008A CN 117551171 A CN117551171 A CN 117551171A
- Authority
- CN
- China
- Prior art keywords
- pea peptide
- intestinal
- preparing
- peptide
- pea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 104
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000000968 intestinal effect Effects 0.000 claims abstract description 23
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 18
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 11
- 239000003629 gastrointestinal hormone Substances 0.000 claims abstract description 10
- -1 polyethylene Polymers 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 239000004698 Polyethylene Substances 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 230000008944 intestinal immunity Effects 0.000 claims abstract description 5
- 229920000573 polyethylene Polymers 0.000 claims abstract description 5
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 208000035475 disorder Diseases 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 5
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 239000007974 sodium acetate buffer Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 230000007413 intestinal health Effects 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 claims 1
- 235000010582 Pisum sativum Nutrition 0.000 description 101
- 241000219843 Pisum Species 0.000 description 96
- 241000699670 Mus sp. Species 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000057297 Pepsin A Human genes 0.000 description 8
- 108090000284 Pepsin A Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 229940111202 pepsin Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 7
- 101710176384 Peptide 1 Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- 102000002419 Motilin Human genes 0.000 description 6
- 101800002372 Motilin Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 208000007882 Gastritis Diseases 0.000 description 5
- 108010084695 Pea Proteins Proteins 0.000 description 5
- 240000004713 Pisum sativum Species 0.000 description 5
- 102000005157 Somatostatin Human genes 0.000 description 5
- 108010056088 Somatostatin Proteins 0.000 description 5
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 5
- 210000004913 chyme Anatomy 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000001630 jejunum Anatomy 0.000 description 5
- 235000019702 pea protein Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 5
- 229960000553 somatostatin Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000023652 chronic gastritis Diseases 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
- 241001473949 Helicobacter pylori NCTC 11637 = CCUG 17874 = ATCC 43504 Species 0.000 description 2
- 241000606860 Pasteurella Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940099472 immunoglobulin a Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LVVHLRGIYZFSEL-UHFFFAOYSA-N 2-methoxyethyl n-[2-[2-[2-[2-(4-oxobutoxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate Chemical compound COCCOC(=O)NCCOCCOCCOCCOCCCC=O LVVHLRGIYZFSEL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000209433 Brasenia Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001646834 Mesona Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101710117021 Tyrosine-protein phosphatase YopH Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
本发明涉及豌豆肽技术领域,具体涉及豌豆肽、修饰豌豆肽的制备方法及改善胃肠道功能的用途。该豌豆肽的氨基酸序列如SEQ ID NO.1所示。该修饰豌豆肽的制备方法是将如SEQ ID NO.1所示的豌豆肽与单甲氧基聚乙二醇‑丁醛反应制得。该用途包括制备肠道抗菌或抑菌产品、制备提高肠道免疫功能产品、制备治疗肠道炎症产品、制备改善炎症肠道形态产品、制备改善胃肠激素紊乱产品和制备提高肠道短链脂肪酸含量产品。
Description
技术领域
本发明涉及豌豆肽技术领域,具体涉及豌豆肽、修饰豌豆肽的制备方法及改善胃肠道功能的用途。
背景技术
豌豆,学名Pisum sativum Linn.,其营养丰富,其淀粉含量55~68%,而蛋白含量20~30%,粗纤维含量8~10%,脂肪含量低于2%。由于豌豆含有丰富的淀粉,除食用外,主要用于生产豌豆淀粉及相关产品。豌豆蛋白是豌豆的重要组成部分,其生物价48~64%,功效比0.6~1.2,且不易过敏,具有较高的营养价值。豌豆蛋白的氨基酸比例较为均衡,易于消化吸收,同时赖氨酸含量较高,是一种良好的蛋白质来源。因此,综述近年来豌豆蛋白及其抗氧化肽的提取方法、分析豌豆蛋白的理化性质及其抗氧化肤的生物活性,为豌豆蛋白的生产和综合开发利用提供参考。
发明内容
本发明人经过对豌豆假设蛋白KIW84_055578的氨基酸序列和前期功能研究发现,其中序列中一个短肽具有相较于该假设蛋白特有的生物学功能,即该豌豆肽具有抗菌、抑菌、提高肠道免疫功能、治疗肠道炎症、改善炎症肠道形态、改善胃肠激素紊乱和提高肠道短链脂肪酸含量的功能。
基于此,本发明提供了一种豌豆肽,其氨基酸序列如SEQ ID NO.1所示。
本发明提供了一种修饰豌豆肽的制备方法,将如SEQ ID NO.1所示的豌豆肽与单甲氧基聚乙二醇-丁醛反应。
进一步地,所述豌豆肽与所述单甲氧基聚乙二醇-丁醛的反应加入量为1:2。
进一步地,反应体系为100mM pH5.0的乙酸-乙酸钠的缓冲液。
进一步地,所述反应时间为40~60min。
进一步地,所述反应以乙醇胺为进行终止。
本发明提供了一种所述的制备方法制得的修饰豌豆肽。
本发明提供了一种在制备改善肠道健康的制品中的用途。
本发明提供了一种制得的修饰豌豆肽的如下至少一项用途:
1)制备肠道抗菌或抑菌产品;
2)制备提高肠道免疫功能产品;
3)制备治疗肠道炎症产品;
4)制备改善炎症肠道形态产品;
5)制备改善胃肠激素紊乱产品;
6)制备提高肠道短链脂肪酸含量产品。
附图说明
图1为豌豆肽修饰产物的ZORBAX SB-C18反相色谱图,A为实验组修饰反应产物,B为对照组修饰反应产物。
图2为豌豆肽(Pep)和修饰豌豆肽(Mod-pep1)的时间-杀菌曲线。
图3为不同pH值下豌豆肽(Pep)、修饰豌豆肽1(Mod-pep1)和修饰豌豆肽2(Mod-pep2)的杀菌效率,“*”表示统计学差异,p<0.05。
图4为胃蛋白酶(Pepsin,3000-3500NFU)、胰蛋白酶(Trypsin,250NFU)和α-糜蛋白酶(α-chymotrypsin,1200U)分别处理豌豆肽(Pep)、修饰豌豆肽(Mod-pep1)和修饰豌豆肽(Mod-pep2)后的杀菌效率,“*”表示统计学差异,p<0.05。
图5为模型组(MOD)、实验组I(EXP1)和实验组II(EXP2)的小鼠十二指肠(duodenum)、空肠(jejunum)和回肠(ileum)中sIgA的表达量,“*”表示统计学差异,p<0.05。
图6为正常组(NOM)、模型组(MOD)、实验组I(EXP1)和实验组II(EXP2)的小鼠肠道中的乙酸含量,“*”表示统计学差异,p<0.05。
图7为正常组(NOM)、模型组(MOD)、实验组I(EXP1)和实验组II(EXP2)的小鼠肠道中的丙酸含量,“*”表示统计学差异,p<0.05。
图8为正常组(NOM)、模型组(MOD)、实验组I(EXP1)和实验组II(EXP2)的小鼠肠道中的丁酸含量,“*”表示统计学差异,p<0.05。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。本发明中未详细单独说明的试剂均为常规试剂,均可从商业途径获得;未详细特别说明的方法均为常规实验方法,可从现有技术中获知。
实施例1、豌豆肽的合成
以NCBI公开的>KAI5410143.1hypothetical protein KIW84_055578豌豆(Pisumsativum L.)蛋白氨基酸序列和前期实验研究为依据,本发明主要集中研究豌豆肽ISQIQRPVKELAFP的相关生物学活性。为此,采用相册的化学固相合成方法合成该豌豆肽,所得豌豆肽具有良好的水溶性,分子量为1625.91g/mol,等电点为10.12左右,-20℃冰箱中长期保存。
实施例2、豌豆肽的修饰
即使本发明制得的豌豆肽具有水溶性高的特点,但在生物体内也由于其水溶性高而导致易于被水解酶破坏、易于被肾小球滤过清除等造成其在体内不易被吸收等问题。因此,本实施例利于聚乙二醇对豌豆肽进行修饰,得到了一种聚乙二醇修饰的豌豆肽。具体如下:
1、修饰反应
实验组:以100mM pH5.0的乙酸-乙酸钠为缓冲体系,于20℃条件下进行反应,反应体系中豌豆肽初始浓度为1.5mg/mL,用mPEG-ButyrALD 5000(单甲氧基聚乙二醇-丁醛,分子量为M.W.5000,广东翁江化学试剂有限公司)为修饰剂初始浓度为1.5mg/mL,充分反应50min,加入过量乙醇胺(20mg/mL,加量为总反应体积的一半)终止反应,并稀释5倍后进行产物分析,得到修饰豌豆肽1。
对照组:用mPEG-ButyrALD 5000(单甲氧基聚乙二醇-丁醛,分子量为M.W.20000Da,广东翁江化学试剂有限公司),其他反应条件与上述相同,得到修饰豌豆肽2。
2、修饰产物分析
利于ZORBAX SB-C18反相柱进行梯度洗脱,流动相A相:100mM乙酸-乙酸钠缓冲液(pH5.0)(含0.1三氟乙酸,w/v);B相:甲醇含0.1三氟乙酸,w/v);流速0.9mL/min;检测波长280nm。梯度洗脱程序为:0→50min,95%A→20%A。标准曲线:精密称取50mg豌豆肽,用100mM乙酸-乙酸钠缓冲液(pH5.0)配置成不同梯度,以上述色谱条件进样20μL,建立色谱峰面积与相应豌豆肽浓度的标准曲线。结果如图1所示,在280nm条件下,50min的反应时间可以得到大量修饰豌豆肽,而对照组中的修饰豌豆肽色谱峰面积较小(说明其反应收率较低)。
3、修饰豌豆肽的分离纯化
将上述反应产物上样至Sp Sepharose Fast Flow(柱体积10ml)进行层析纯化,以pH=4、含0.5M的NaCl的0.02M醋酸盐液以0%→100%体系20个柱体积能够得到修饰豌豆肽的纯的为96%以上(上述液相纯度)。
实施例3、豌豆肽及修饰豌豆肽的体外杀菌活性和抗逆性
1、试剂及仪器
豌豆肽由奥林贝尔科技有限公司提供,其通过枯草芽孢杆菌表达系统分泌而来;LB培养基、MH肉汤培养基购于青岛海博生物;氨苄青霉素购于生工生物工程;麦氏比浊管购于中诺泰安;胃蛋白酶、胰蛋白酶和α-糜蛋白酶购于北京索莱宝科技有限公司;pH计(上海雷兹phs-3c);酶标仪(BioTek,美国)等。
2、试验菌株和试验品
大肠杆菌ATCC25922、鼠伤寒沙门氏菌ATCC14028、金黄色葡萄球菌ATCC25923、幽门螺杆菌ATCC43504和巴氏杆菌ATCC19427均来源于美国标准菌种收藏所(American TypeCulture Collection;ATCC,美国)。
试验品为上述实施例1提供的豌豆肽和实施例2提供的修饰豌豆肽。
3、抑菌效果测定
豌豆肽及修饰豌豆肽的杀菌效果通过抑菌圈-牛津杯法进行直观评价,以最小抑菌浓(MIC)确定豌豆肽和修饰豌豆肽的抑菌效果。MIC通过液体微量稀释法来测定。具体步骤如下:1)制备LB固体培养基,灭菌后在超净工作台上接种细菌,放入37℃恒温培养箱内培养16-24h;2)制备MH肉汤培养基,灭菌后在LB固体培养基上挑取单克隆至MH肉汤培养基中,37℃、220r/min培养8h;3)取10mLMH肉汤培养基于灭菌的离心管中,用生理盐水稀释到0.5个麦氏比浊管,此时浓度约为1.5×108CFU/mL;4)再加入刚配制的无菌的MH肉汤培养基,稀释到约5×105CFU/mL;5)在96孔板上加入180μL、5×105CFU/mL上述溶液;6)并加入20μL的豌豆肽溶液,轻轻吹打混合。7)放入37℃恒温培养箱培养16-24h,肉眼观察细菌的生长情况,未变浑浊的浓度即为最小抑菌浓度。
结果可知,豌豆肽对大肠杆菌ATCC25922、鼠伤寒沙门氏菌ATCC14028、巴氏杆菌ATCC19427、幽门螺杆菌ATCC43504和金黄色葡萄球菌ATCC25923的MIC分别是0.25、0.5、0.7、0.6和1.4μg/mL;实验组得到的修饰豌豆肽的MIC分别是0.5、0.5、0.8、0.8和1.6μg/mL。而对照组得到的修饰豌豆肽的MIC分别是1.6、0.8、1.2、5.0和5.0μg/mL。
4、豌豆肽及修饰豌豆肽的时间-杀菌曲线
时间-杀菌曲线也是反映抗菌肽的杀菌效果之一,通过在时间和剂量上比较,初步显示了豌豆肽发挥杀菌作用的动力学,具体步骤如下:1)将大肠杆菌作为指示菌,接种于LB固体培养基上,37℃培养24h后,挑取单克隆至MH肉汤培养基,培养8h;2)将上述菌液稀释至1×106CFU/mL,取180μL于96孔板中;3)取0、0.25、1和10倍的MIC值的浓度的豌豆肽20μL,加入到96孔板中,设置三个复孔;4)将96孔板放入37℃恒温培养箱16h,并在1、2、4、8和16h时,检测每个孔的OD值,统计数据,根据公式结算结果。5)公式如下:杀菌效率=(A-A1)/(A1-A2)×100%,其中,A、A1和A2代表阴性对照、不同处理因素和阳性对照试验在反应之后紫外分光光度计A520波长下的吸光值。
本试验以大肠杆菌ATCC25922为指示菌,选用1倍MIC值的豌豆肽或修饰豌豆肽1以不同时间点(第1、2、4、8、16h)检测OD值,得出图2。由图2得知,随着杀菌时间的延长,豌豆肽或修饰豌豆肽在第6h杀菌效率达到峰值后开始下降;下降到第10h后,杀菌效率开始趋于平缓。
5、豌豆肽的抗逆性测定
抗逆性检测主要包括pH和蛋白酶对豌豆肽发挥抗菌效果的影响,具体步骤为:2)利用pH计制备pH为2.0、3.0、4.0、5.0、6.0、7.0的6份溶液,取100μL不同pH的溶液等体积与40μg/mL的豌豆肽均匀混合,在37℃的水浴锅中孵育30min,设置三个重复;4)配制胃蛋白酶(3000-3500NFU)、胰蛋白酶(250NFU)和α-糜蛋白酶(1200U)溶液,取100μL等体积与40μg/mL的豌豆肽均匀混合,在37℃的水浴锅中孵育30min,设置三个重复;5)取20μL处理后的豌豆肽于96孔板中,并加入180μL备用的5×105的菌液,吹打混匀,放置37℃恒温培养箱中培养24h,检测OD值;6)计算公式与时间—杀菌曲线计算公式一致。
结果如图3所示(图3中,“*”表示不同pH值下相对于豌豆肽的杀菌效率有显著性差异,p<0.05),豌豆肽在不同pH值下的杀菌效率不如修饰豌豆肽1,说明修饰豌豆肽1更适合于体内胃部酸性环境进行杀菌或抑菌,并且对照组制得的修饰豌豆肽2相对于豌豆肽在不同pH值下的杀菌效率无明显提高。如图4所示,胃蛋白酶(Pepsin,3000-3500NFU)、胰蛋白酶(Trypsin,250NFU)和α-糜蛋白酶(α-chymotrypsin,1200U)分别处理豌豆肽及修饰豌豆肽1后,豌豆肽的抗菌活性显著降低,而修饰豌豆肽1无明显降低,说明采用上述修饰方式得到修饰豌豆肽提高了豌豆肽的抗菌性,更利于其体内发挥抗菌功能。
实施例4、体内试验
1、材料与方法
(1)实验动物和试验品
SPF级昆明种小鼠,由济南朋悦实验动物繁育有限公司提供,实验动物生产许可证号为SCXK鲁)2019-0003。环境温度22℃±2℃,相对湿度50%±10%,光照周期设定为12h明暗自动控制。试验品为上述实施例提供的豌豆肽及修饰豌豆肽(实验组制得的修饰豌豆肽),用无菌水稀释以便进行小鼠灌胃。
(2)急性毒性试验
以20g/kg·bw的剂量连续灌胃14d后,两性别小鼠状态良好,行为正常,未见明显的中毒症状及死亡。将受试动物处死后进行解剖检查,肝、脾、肾、心脏、肺、胃和肠等主要器官,均未见明显异常改变。认为受试样品对SPF级昆明种小鼠的最大耐受剂量(MTD)均大于20g/kg·bw(LD50>20g/kg·bw),根据经口急性毒性分级标准划为实际无毒级别。
(3)慢性胃炎小鼠模型建立及分组实验
慢性胃炎小鼠模型的建立方法为:1×109CFU/mL Hp菌液(幽门螺杆菌,Hp标准菌株SSI,中国药品生物制品鉴定所),灌胃SPF级昆明种小鼠,剂量为0.2mL,每2d灌胃一次,连续5次,灌胃前6h和灌胃后0.5h禁食禁水。距离末次灌胃Hp细菌悬液结束后4周,麻醉处死小鼠,取胃窦组织用于快速尿素酶实验、病理学检测和Hp培养实验,革兰染色结果呈红色、快速尿素酶结果阳性(酚红颜色变为红色)、Hp细菌培养结果阳性判定为Hp感染,则表示Hp感染模型制备成功。
分组实验,依次分为正常组、模型组、实验组I和实验组II。正常组和模型组不进行灌胃。实验组I以20g/kg·bw的剂量连续灌胃豌豆肽慢性胃炎模型小鼠14d。实验组II以20g/kg·bw的剂量连续灌胃修饰豌豆肽慢性胃炎模型小鼠14d。
(3)组织样品制备
分别取的15d小鼠,空腹8h后,从各处理中的每个重复随机挑选一只体重接近各重复平均体重的正常小鼠,将十二指肠、空肠、回肠肠段分开,剪去各肠段两端部分,取中间较好肠段分成两段:一段用生理盐水轻轻洗去内容物,取中部大约3cm左右放入4%的多聚甲醛中固定,转入4℃保存,用于制作石蜡切片;另一段用生理盐水轻轻洗去内容物后纵向剪开,轻轻刮取黏膜组织于冻存管,放入液氮暂存后转入-80℃保存,用于测定小肠营养物质转运载体的表达。将盲肠分出,轻轻挤出盲肠食糜,装入无菌的冻存管中,液氮暂存后转至-80℃保存。
(4)肠组织形态
从各组小鼠内脏团中分离出肠道,取中肠和后肠内容物即肠道食糜至1.5mL冻存管用于肠道微生物和酶活性的分析(刮取肠道食糜等内容物时,注意防止肠道黏膜损伤),然后分别取中肠、后肠肠道组织于1.5mL离心管用于肠道基因荧光定量表达分析,液氮速冻用,使用前在-80℃条件下储存,采用尼康Ni-E/Ni-U型正置荧光显微镜进行观察和计算肠绒毛高度IVH/μm、肠绒毛宽度IVW/μm和肌层厚度IWT/μm。
(5)胃肠激素水平检测
在处死小鼠前,在麻醉状态下采集0.2mL眼球取血置于抗凝管中,离心,收集上清液于-80℃保存。随后随机处死6只小鼠,分离胃组织,取0.2g胃组织,研磨制成组织匀浆,离心,取上清液存储于-80℃。采用酶联免疫吸附法检测血浆和胃组织上清液中的胃动素(MTL)、5-色羟胺(5-HT)、胃泌素(Gas)、生长抑素(SS)、胃饥饿素(Grelin)水平,MTL试剂盒(上海莼试生物技术有限公司),其他试剂盒(上海雅吉生物科技有限公司),操作严格参照试剂盒说明书进行。
(6)小肠分泌型免疫球蛋白A(sIgA)的表达量
小肠分泌型免疫球蛋白A(sIgA)检测采用免疫组化的方法,山羊抗鼠sIgA单克隆抗体(PMA04C020258,Perfemiker)作为一抗,采用光学显微镜对小肠sIgA阳性信号进行定性分析,利用Image-Pro Plus 6.0软件进行平均光密度(Mean of iod)半定量分析。
(7)肠道食糜短链脂肪酸测定
称取冷冻干燥后的肠道食糜样品100mg,加1mL水混匀,加200μL50%硫酸,再加1000mg/L的内标(环己酮)溶液50μL和乙醚1mL匀浆1min,于4℃、12000rpm离心10min,取上清上气相色谱质谱联用仪机器上(日本,岛津,GCMS QP2010-Ultra)测定。利用GCMSSolution软件进行积分,利用标准曲线进行含量计算得到短链脂肪酸的值。
2、结果
表1示出了各组小鼠肠道形态指标,其中,“*”表示相对于模型组具有显著性差异(P<0.05),“#”表示相对于正常组具有显著性差异(P<0.05)。由表1可知,实验组II相对于正常组和模型组均具有显著性差异,说明本发明提供的修饰豌豆肽能够改善炎症小鼠的肠道形态。
表1各组小鼠肠道形态(平均值±标准误差)
表2各组小鼠胃肠激素水平(平均值±标准误差)
5-HT(ng/mL) | Gas(pg/mL) | MTL(pg/mL) | SS(pg/mL) | Grelin(pg/mL) | |
正常组 | 19.03±1.97 | 33.42±4.16 | 304.23±13.26 | 249.37±12.36 | 149.03±6.32 |
模型组 | 32.25±2.45 | 53.19±7.05 | 378.23±26.02 | 187.03±10.78 | 98.72±7.84 |
实验组I | 21.03±2.05* | 37.25±4.78* | 312.18±17.03* | 234.25±14.78* | 139.36±10.36* |
实验组II | 14.63±1.92*# | 25.84±6.09*# | 268.52±20.24*# | 256.92±16.33*# | 152.84±9.09*# |
表2示出了各组小鼠胃肠激素水平,其中,“*”表示相对于模型组具有显著性差异(P<0.05),“#”表示相对于正常组具有显著性差异(P<0.05)。由表2可知,实验组II相对于正常组和模型组均具有显著性差异。Hp感染会影响宿主胃肠动力、胃肠激素分泌,本研究发现Hp感染小鼠外周血和胃组织5-HT、Gas、MTL水平升高,而SS和Grelin水平降低。5-HT可参与消化系统调节,大部分5-HT合成分泌来自于消化道。Gas是由胃黏膜G细胞分泌的具有刺激胃酸分泌、胃蛋白酶分泌的胃肠激素,可促进细胞生长功能。Hp毒力蛋白可激活Gas启动子,促进Gas分泌。SS可通过旁分泌方式抑制胃酸、胃蛋白酶分泌,还对Gas释放有抑制作用,影响胃肠道功能运转,发挥胃黏膜保护作用。MTL参与胃肠运动、胃肠道水和电解质的运输过程,Grelin在食欲调节、胃排空、胃酸分泌过程中发挥重要作用,Hp感染者胃黏膜Grelin表达水平降低,其水平抑制程度与胃黏膜损伤严重程度有关,Grelin水平持续性降低可引起细胞免疫反应以及慢性活动性胃炎发生。本研究结果显示,本发明提供的豌豆肽及修饰豌豆太肽能够调节Hp感染所致的胃肠激素紊乱。
如图5所示,“*”表示实验组II相对于模型组具有显著性差异(P<0.05),由此表明对Hp模型小鼠灌胃修饰豌豆肽能够显著提供其十二指肠、回肠和空肠sIgA的表达量,对空肠的肠道健康有着卓著成效。
如图6所示,“*”表示实验组II相对于模型组和正常组具有显著性差异(P<0.05)。由此表明,对Hp模型小鼠灌胃修饰豌豆肽能够小鼠肠道中的短链脂肪酸含量。短链脂肪酸通过降低鱼类胃和肠道的PH值以及通过酸的离解和细菌细胞中阴离子的产生抑制革兰氏阴性细菌的生长来调节宿主的生理状态。短链脂肪酸是由小肠内不被消化吸收的复杂碳水化合物进入大肠后由厌氧微生物发酵而产生的,其中乙酸、丙酸和丁酸所占比例高达85%。短链脂肪酸SCFAs具有调节肠道免疫功能以及降低肠道通透性等重要的生理功能,并且是肠道上皮细胞以及肝脏能量的重要来源之一。丁酸对很多突变物质具有抑制活性,是肠道中强的抗癌物质,丁酸是结肠细胞首选的能源物质,并与细胞凋亡和细胞分化的调控有关。由此可见,本发明提供的修饰豌豆肽不仅能够提高小鼠肠道中的短链脂肪酸含量,还能改善肠道免疫功能,降低肠道通透性,调节肠道细胞凋亡和分化,进而调控肠道健康。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到的变化或替换,都应涵盖在本发明的保护范围之内。
Claims (9)
1.一种豌豆肽,其氨基酸序列如SEQ ID NO.1所示。
2.一种修饰豌豆肽的制备方法,其特征在于,将如SEQ ID NO.1所示的豌豆肽与单甲氧基聚乙二醇-丁醛反应。
3.根据权利要求2所述的制备方法,其特征在于,所述豌豆肽与所述单甲氧基聚乙二醇-丁醛的反应加入量为1:1。
4.根据权利要求2所述的制备方法,其特征在于,反应体系为100mM pH5.0的乙酸-乙酸钠的缓冲液。
5.根据权利要求2所述的制备方法,其特征在于,所述反应时间为40~60min。
6.根据权利要求2所述的制备方法,其特征在于,所述反应以乙醇胺进行终止。
7.权利要求2~6任一所述的制备方法制得的修饰豌豆肽。
8.权利要求1所述的豌豆肽在制备改善肠道健康的制品中的用途。
9.权利要求2~6任一所述的制备方法制得的修饰豌豆肽的如下至少一项用途:
1)制备肠道抗菌或抑菌产品;
2)制备提高肠道免疫功能产品;
3)制备治疗肠道炎症产品;
4)制备改善炎症肠道形态产品;
5)制备改善胃肠激素紊乱产品;
6)制备提高肠道短链脂肪酸含量产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311359008.2A CN117551171A (zh) | 2023-10-19 | 2023-10-19 | 豌豆肽、修饰豌豆肽的制备方法及改善胃肠道功能的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311359008.2A CN117551171A (zh) | 2023-10-19 | 2023-10-19 | 豌豆肽、修饰豌豆肽的制备方法及改善胃肠道功能的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117551171A true CN117551171A (zh) | 2024-02-13 |
Family
ID=89811839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311359008.2A Pending CN117551171A (zh) | 2023-10-19 | 2023-10-19 | 豌豆肽、修饰豌豆肽的制备方法及改善胃肠道功能的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117551171A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013073648A1 (ja) * | 2011-11-18 | 2013-05-23 | 不二製油株式会社 | 経口性抗炎症機能剤 |
US20190111144A1 (en) * | 2016-04-06 | 2019-04-18 | Nanjing Anji Biological Technology Co.,Ltd | Polyethylene glycol-modified angiogenesis inhibitor hm-1 and application thereof |
-
2023
- 2023-10-19 CN CN202311359008.2A patent/CN117551171A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013073648A1 (ja) * | 2011-11-18 | 2013-05-23 | 不二製油株式会社 | 経口性抗炎症機能剤 |
US20190111144A1 (en) * | 2016-04-06 | 2019-04-18 | Nanjing Anji Biological Technology Co.,Ltd | Polyethylene glycol-modified angiogenesis inhibitor hm-1 and application thereof |
Non-Patent Citations (1)
Title |
---|
FATOU NDIAYE等: "Anti-oxidant, anti-inflammatory and immunomodulating properties of an enzymatic protein hydrolysate from yellow field pea seeds", EUROPEAN JOURNAL OF NUTRITION, vol. 51, 27 March 2011 (2011-03-27), pages 29, XP035006350, DOI: 10.1007/s00394-011-0186-3 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Adhikari et al. | Effect of dietary fructooligosaccharide supplementation on internal organs Salmonella colonization, immune response, ileal morphology, and ileal immunohistochemistry in laying hens challenged with Salmonella enteritidis | |
CN110305222B (zh) | 一种兼具解毒、抗炎、抗细胞凋亡、保护肠道屏障及促进伤口愈合的杂合肽及其应用 | |
CN112011481B (zh) | 一株防治畜禽细菌性腹泻的罗伊氏乳杆菌及其应用 | |
Yi et al. | Anethole attenuates enterotoxigenic Escherichia coli-induced intestinal barrier disruption and intestinal inflammation via modification of TLR signaling and intestinal microbiota | |
CN113999797B (zh) | 一株改善肉鸡生产性能和免疫水平的乳酸片球菌及其筛选方法与应用 | |
CN114350578B (zh) | 一株产溶菌酶并高效拮抗多药耐药幽门螺杆菌的植物乳杆菌lp1z及其应用 | |
CN116064286B (zh) | 具有改善非酒精性肝病的瑞士乳杆菌zjuids11及其应用 | |
CN110484467B (zh) | 一株多粘芽孢杆菌及其产生的抗菌肽和应用 | |
CN116396974A (zh) | 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用 | |
CN112239741B (zh) | 一种Megasphaera属的细菌MNC-992及其培养方法和应用 | |
CN113015790A (zh) | 含有属于帕拉普氏菌属的细菌作为有效成分的用于抑制胰蛋白酶活性的组合物 | |
CN114381398A (zh) | 具有改善酒精性肝病的瑞士乳杆菌zjuids12及其应用 | |
CN112322553B (zh) | 一种抗艰难梭菌的乳酸乳球菌及其应用 | |
CN116083325B (zh) | 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用 | |
CN117551171A (zh) | 豌豆肽、修饰豌豆肽的制备方法及改善胃肠道功能的用途 | |
CN117448213A (zh) | 一种抑制产气荚膜梭菌的植物乳杆菌及其后生元和应用 | |
CN113151069A (zh) | 一种枯草芽孢杆菌及其在制备抗菌肽、饲料中的应用 | |
CN117099962A (zh) | 发酵粘液乳杆菌LFPerfectus001的新应用 | |
CN110463824B (zh) | 奥氏乳杆菌菌株bslo 1801及其在蛋鸡产蛋中的应用 | |
CN114908009A (zh) | 一株口粘液乳杆菌pr63及其应用 | |
Lin et al. | Effects of lactic acid bacteria-fermented formula milk supplementation on colonic microbiota and mucosal transcriptome profile of weaned piglets | |
CN113308416B (zh) | 一株具有抑制肾结石形成能力的植物乳杆菌及其应用 | |
CN116987612B (zh) | 一种耐盐芽孢杆菌sw207及其应用 | |
CN116445340B (zh) | 提高抗病性和抑制致病菌生长的民猪肠源暹罗芽孢杆菌 | |
CN116103193B (zh) | 一种益生菌粉剂及其在缓解结肠炎中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |